title: Warnings against candesartan in pregnancy are not implemented in physicians' practice.
authors.forename: Camilla
authors.initials: C
authors.lastname: Borthen
authors.forename: Bjørn
authors.initials: B
authors.lastname: Oglaend
authors.forename: Torbjørn
authors.initials: T
authors.lastname: Eggebøe
authors.forename: Christian Lycke
authors.initials: CL
authors.lastname: Ellingsen
authors.forename: Jan
authors.initials: J
authors.lastname: Schjøtt
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D004359:Drug Therapy, Combination; D005260:Female; D005313:Fetal Death / Q000139:chemically induced*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D016104:Oligohydramnios / Q000139:chemically induced*; D010818:Practice Patterns, Physicians'; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D013777:Tetrazoles / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D006852:Hydrochlorothiazide; C081643:candesartan